Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 9:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 500 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diabetes Mellitus ( Type 1 and Type 2) Clear all
Completed Phase 1 Interventional

Single Cohort 4-period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With Ranolazine

NCT01546597
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Metformin, Ranolazine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
30 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 11, 2012 · Synced Oct 31, 2026, 9:03 AM EDT
Not listed Phase 4 Interventional

A Randomized Controlled Trial Evaluating One Drop | Premium With Afrezza vs. One Drop | Premium Alone

NCT03313960
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Afrezza plus One Drop | Premium, One Drop | Premium
Drug · Other
Lead sponsor
Informed Data Systems, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 31, 2026, 9:03 AM EDT
Completed Phase 2 Interventional Results available

Sensor-Augmented Insulin Delivery: Insulin Plus Glucagon Versus Insulin Alone

NCT00797823
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Insulin, Asp(B28)-, Glucagon, Placebo
Drug
Lead sponsor
Legacy Health System
Other
Eligibility
21 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 7, 2011 · Synced Oct 31, 2026, 9:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Assess the Bioequivalence of Dapagliflozin/Metformin XR Fixed-dose Combination Tablets in Healthy Subjects

NCT02637037
View directory record Official record
Conditions
Bioequivalence, Fixed Dose Combination Tablets, Healthy Male and Female Subjects
Interventions
dapagliflozin/metformin XR 5/500 mg test drug (Mount Vernon), dapagliflozin/metformin XR 5/500 mg reference drug (Humacao), dapagliflozin/metformin XR 10/1000 mg test drug (Mount Vernon), dapagliflozin/metformin XR 10/1000 mg reference drug (Humacao)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Oct 31, 2026, 9:03 AM EDT
Completed Phase 1Phase 2 Interventional

Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled, Study to Assess Safety, Tolerability, PK and PD Response of PB1023 Injection Following Single and Multiple SQ Doses in Adults With Type 2 Diabetes Mellitus

NCT01236404
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Single Subcutaneous Dose (Part A) of PB1023 or Placebo (0.9% NaCl), Multiple (Four Weekly) Subcutaneous Injections (Part B) of PB1023 or Placebo (0.9% NaCl)
Drug
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
3
States / cities
Walnut Creek, California • Saint Paul, Minnesota • Renton, Washington
Source: ClinicalTrials.gov public record
Updated May 21, 2013 · Synced Oct 31, 2026, 9:03 AM EDT
Completed Phase 2 Interventional

Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy

NCT00406458
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Polyneuropathy
Interventions
SB-509, Normal Saline
Drug · Other
Lead sponsor
Sangamo Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
14
States / cities
La Jolla, California • Lakewood, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2012 · Synced Oct 31, 2026, 9:03 AM EDT
Completed Not applicable Interventional

Weight Inclusive and Adaptive Strategies to Enhance Cardiometabolic Health in Black Adults

NCT06284681
View directory record Official record
Conditions
Obesity, Prehypertension, Hypertension, PreDiabetes, Type 2 Diabetes, Dyslipidemia
Interventions
Weight-focused health coaching, Weight-neutral health coaching, Intensify lifestyle approach, Augment with enhanced medical management
Behavioral · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 31, 2026, 9:03 AM EDT
Completed Phase 3 Interventional Results available

Adjunctive Metformin Therapy in Double Diabetes

NCT01334125
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Metformin, Placebo
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
10 Years to 20 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 4, 2016 · Synced Oct 31, 2026, 9:03 AM EDT
Recruiting Not applicable Interventional

NOURISH - A Healthcare-community Partnership to Improve Nutrition for Optimal Glycemic Control and Pregnancy Outcomes With Pregestational Diabetes

NCT07560813
View directory record Official record
Conditions
Type 2 Diabetes, Type 1 Diabetes, Pregnancy, High Risk
Interventions
Mid-Ohio Food Farmacy (MOF+) produce delivery, Nutrition education with Dining with Diabetes (DWD), Health Impact Ohio Central Ohio Pathways Hub to address unmet social needs
Dietary Supplement · Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older · Female only
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 31, 2026, 9:03 AM EDT
Terminated Not applicable Interventional Results available

Diabetic Foot Ulcer Study Comparing Cytal Wound Matrix 1-Layer to Standard of Care

NCT03626623
View directory record Official record
Conditions
Diabetes, Diabetic Foot, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Interventions
Cytal Wound Matrix 1-Layer, Standard of Care (SOC)
Device · Other
Lead sponsor
Integra LifeSciences Corporation
Industry
Eligibility
21 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
3
States / cities
Fresno, California • New Orleans, Louisiana • Hyattsville, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 25, 2021 · Synced Oct 31, 2026, 9:03 AM EDT
Not listed Not applicable Interventional

Improving Diabetes Equity and Advancing Care Study

NCT06040463
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
Diabetes Self-Management Training (DSMT), Remote Glucose Monitoring (RGM), Community Health Worker tailored support
Behavioral
Lead sponsor
Sinai Health System
Other
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 7, 2023 · Synced Oct 31, 2026, 9:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Metabolic Causes of Thrombosis in Type 2 Diabetes - Question 1

NCT00574665
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Hyperinsulinemic Hyperglycemic Clamp
Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 11, 2014 · Synced Oct 31, 2026, 9:03 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)

NCT06562907
View directory record Official record
Conditions
Weight Management
Interventions
GS-4571, Placebo, Omeprazole
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
3
States / cities
Miami, Florida • San Antonio, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 31, 2026, 9:03 AM EDT
Completed Phase 1 Interventional Results available

Study of Multiple Oral Doses of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus

NCT05158244
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
PF-07081532, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 12, 2024 · Synced Oct 31, 2026, 9:03 AM EDT
Completed No phase listed Observational Results available

Assessment of Mealtime Bolus Insulin Behavior

NCT03368807
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
Continuous Glucose Monitoring, Insulin Lispro
Device · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
21 Years to 65 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
6
States / cities
Escondido, California • Los Angeles, California • Ventura, California + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2019 · Synced Oct 31, 2026, 9:03 AM EDT
Completed No phase listed Observational

Investigating Novel Predictions of Hypoglycemia Occurrence in Real-world Models

NCT04219514
View directory record Official record
Conditions
Hypoglycemia, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Interventions
Not listed
Lead sponsor
Stewart Harris
Other
Eligibility
18 Years to 90 Years
Enrollment
1,206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Oct 31, 2026, 9:03 AM EDT
Completed Phase 2 Interventional Results available

BMS - Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Dapagliflozin in Type 1 Diabetes

NCT01498185
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Dapagliflozin, Placebo matching Dapagliflozin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
12
States / cities
Chula Vista, California • San Diego, California • Torrance, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2017 · Synced Oct 31, 2026, 9:03 AM EDT
Completed No phase listed Observational

Green Digital Diabetes Waste Project

NCT06071325
View directory record Official record
Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Interventions
Not listed
Lead sponsor
Florida State University
Other
Eligibility
18 Years to 120 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Burlingame, California • Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 31, 2026, 9:03 AM EDT
Terminated Phase 3 Interventional

Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus

NCT04606576
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Placebo, ORMD-0801 QD, ORMD-0801 BD
Other · Drug
Lead sponsor
Oramed, Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
710 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Tustin, California
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Oct 31, 2026, 9:03 AM EDT
Completed Phase 1 Interventional Results available

Safety and Tolerability of Ascending Intravenous Doses of PF-05231023 In Adult Subjects With Type 2 Diabetes

NCT01396187
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
PF-05231023, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
30 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
5
States / cities
Chula Vista, California • Miami, Florida • South Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2015 · Synced Oct 31, 2026, 9:03 AM EDT
Recruiting Phase 4 Interventional

Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes

NCT06706284
View directory record Official record
Conditions
Spinal Cord Injuries, Type 2 Diabetes
Interventions
Semaglutide Injectable Product, Placebo
Drug · Other
Lead sponsor
Marzieh Salehi
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 31, 2026, 9:03 AM EDT
Completed Phase 3 Interventional Results available

Protein Kinase C (PKC) Inhibitor-Diabetic Retinopathy Phase 3 Study

NCT00604383
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
ruboxistaurin, placebo
Drug
Lead sponsor
Chromaderm, Inc.
Industry
Eligibility
18 Years and older
Enrollment
685 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 6, 2016 · Synced Oct 31, 2026, 9:03 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of B I1356 (Linagliptin) vs. Placebo Added to Metformin Background Therapy in Patients With Type 2 Diabetes

NCT00601250
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
linagliptin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
701 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
19
States / cities
Chula Vista, California • Spring Valley, California • Walnut Creek, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2014 · Synced Oct 31, 2026, 9:03 AM EDT
Not listed Phase 1Phase 2 Interventional

YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma

NCT05448820
View directory record Official record
Conditions
Advanced Sarcoma, Metastatic Sarcoma, Soft Tissue Sarcoma
Interventions
YH001, Envafolimab, Doxorubicin
Drug
Lead sponsor
Tracon Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
6
States / cities
Santa Monica, California • Chicago, Illinois • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 31, 2026, 9:03 AM EDT